Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.
1968
Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.
Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.
Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.
From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.
The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.
Les Nouvelles - Licensing Executives Society International (LESI)
Stephen (Steve) G. Baxter, Ph.D., is a partner in the firm's Chemical Patent Prosecution and Litigation practice groups. His practice includes all phases of patent prosecution, including the preparation of patent applications, patent litigation in federal district court, client counseling, and due diligence. He is also experienced in § 337 actions at the International Trade Commission.
Formerly an Assistant Professor of Chemistry at Tufts University, with a Ph.D. in organic chemistry, Dr. Baxter possesses a deep understanding of the science underlying his clients’ innovations. He is especially skilled in the prosecution and litigation of a wide range of chemical and pharmaceutical patents and represents numerous large chemical and pharmaceutical companies.
With years of experience both litigating and prosecuting patents, Dr. Baxter readily identifies the points of attack that make a patent vulnerable, crafting patents to avoid later challenges. A skilled strategist, Dr. Baxter advises his clients on patent portfolio management and optimization, patentability, and interference issues.
Dr. Baxter has been an invited lecturer at the MAS program at ETH in Zurich, Switzerland, and many chemical and pharmaceutical companies. He has also published nearly 20 scientific articles in areas such as heterocyclic chemistry and stereochemistry.